Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Controlled Phase I and Sequential Study to Evaluate the Safety and Immunogenicity Following Immunization of GEN2-Recombinant COVID-19 Vaccine (CHO Cells,NVSI-06-08) and Inactivated COVID-19 Vaccine (Vero Cells) in Population Aged 18 Years and Above

NCT05069129 is registered in ClinicalTrials.gov with National Vaccine and Serum Institute, China as lead sponsor.

NCT NCT05069129
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05069129 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Controlled Phase I and Sequential Study to Evaluate the Safety and Immunogenicity Following Immunization of GEN2-Recombinant COVID-19 Vaccine (CHO Cells,NVSI-06-08) and Inactivated COVID-19 Vaccine (Vero Cells) in Population Aged 18 Years and Above
Lead sponsor
National Vaccine and Serum Institute, China
Phase
Phase 1/2
Overall status
Unknown status
Start date
October 14, 2021
Completion date
February 29, 2024
Enrollment
1,848 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

coronavirus infections, covid-19 pneumonia